American Lung Association, Gateway for Cancer Research Partner to Develop Personalized Lung Cancer Vaccine
 CHICAGO, May 3, 2023 /PRNewswire/ -- Gateway for Cancer Research, a nonprofit organization dedicated to funding transformational early phase cancer clinical trials around the world, today announced a new partnership with the American Lung Association Research Institute. The alliance centers on a funding agreement between Gateway and the Lung Association to advance a personalized vaccine trial that aims to train each patient's immune system to combat small cell lung cancer (SCLC). Spearheaded by Jeffrey Ward, MD, PhD, a medical oncologist at Washington University School of Medicine in St. Louis, Missouri, the trial officially began enrolling patients in spring 2022 for what will be a five-year study. Investigators believe it to be the only ongoing trial integrating a personalized vaccine into first-line therapy for SCLC.
- CHICAGO, May 3, 2023 /PRNewswire/ -- Gateway for Cancer Research , a nonprofit organization dedicated to funding transformational early phase cancer clinical trials around the world, today announced a new partnership with the American Lung Association Research Institute .
- The alliance centers on a funding agreement between Gateway and the Lung Association to advance a personalized vaccine trial that aims to train each patient's immune system to combat small cell lung cancer (SCLC).
- An aggressive type of lung cancer, SCLC is estimated to account for approximately 14% of all lung cancer diagnoses.
- Gateway for Cancer Research and the American Lung Association together have contributed $678,668 to support development of the trial vaccine.